Discovery of 4-{1-[({1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl}carbonyl) amino]cyclopropyl}benzoic acid (MF-766), a highly potent and selective EP 4 antagonist for treating inflammatory pain

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 12, 2010, Pages 3760-3763

  Colucci, John ^a   Boyd, Michael ^a   Berthelette, Carl ^a   Chiasson, Jean Francois ^a   Wang, Zhaoyin ^a   Ducharme, Yves ^a   Friesen, Rick ^a   Wrona, Mark ^a   Levesque, Jean Francois ^a   Denis, Danielle ^a   Mathieu, Marie Claude ^a   Stocco, Rino ^a   Therien, Alex G ^a   Clarke, Patsy ^a   Rowland, Steve ^a   Xu, Daigen ^a   Han, Yongxin ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

EP4 antagonist; Inflammatory pain

Indexed keywords

4 [1 [[[1 [4 (TRIFLUOROMETHYL)BENZYL] 1H INDOL 7 YL]CARBONYL]AMINO]CYCLOPROPYL]BENZOIC ACID; MF 766; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT;

ANIMALS; ARTHRITIS; BENZOIC ACIDS; CELLS, CULTURED; DOGS; DRUG DISCOVERY; DRUG STABILITY; HEPATOCYTES; HUMANS; INDOLES; INFLAMMATION; PAIN; PHARMACOKINETICS; RATS; RECEPTORS, PROSTAGLANDIN E; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 77954213066     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.065     Document Type: Article

References (20)

1. R.J. Flower Nat. Rev. Drug Disc. 2 2003 179
2. J.M. McCoy, J.R. Wicks, and L.P. Audoly J. Clin. Invest. 110 2002 651
3. C.-R. Lin, F. Amaya, L. Barrett, H. Wang, J. Takada, T.A. Samad, and C.J. Woolf J. Pharmacol. Exp. Ther. 319 2006 1096
4. P. Clark, S.E. Rowland, D. Denis, M.-C. Mathieu, R. Stocco, H. Poirier, J. Burch, Y. Han, L. Audoly, A.G. Therien, and D. Xu J. Pharmacol. Exp. Ther. 325 2008 425
5. S.D. Solomon, J.J.V. McMurray, M.A. Pfeiffer, J. Wittes, R. Fowler, P. Finn, W.F. Anderson, A. Zauber, E. Hawk, and M. Bertagnolli N. Eng. J. Med. 352 2005 1071
6. N.A. Nussmeier, A.A. Whelton, M.T. Brown, R.M. Langford, A. Hoeft, J.L. Parlow, S.W. Boyce, and K.M. Verbug N. Eng. J. Med. 352 2005 1081
7. R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. Lines, R. Ridell, D. Morton, A. Lanas, M.A. Konstam, and J.A. Baron N. Eng. J. Med. 352 2005 1092
8. B.F. McAdam, F. Catella-Lawson, I.A. Mardini, S. Kapoor, J.A. Lawson, and G.A. FitzGerald Proc. Natl. Acad. Sci. U.S.A. 96 1999 272
9. G.A. FitzGerald, and C. Patrono N. Eng. J. Med. 345 2001 433
10. C.D. Funk, and G.A. FitzGerald J. Cardiovasc. Pharmacol. 50 2007 470
11. J.D. Burch, M. Belley, R. Fortin, D. Deschênes, M. Girard, J. Colucci, J. Farand, A.G. Therien, M.-C. Mathieu, D. Denis, E. Vigneault, J.-F. Lévesque, S. Gagné, M. Wrona, D. Xu, P. Clark, S. Rowland, and Y. Han Bioorg. Med. Chem. Lett. 18 2008 2048
12. Unpublished results: the elimination half-life of the corresponding sulfonamide M1 from MF-310 in rat and dog was estimated to be >24 h. When MF-310 was dosed orally at 20 mg/kg/day for 5 days in rats, M1 levels at 24 h increased from 1.4 μM after the first dose to 4.6 μM after the last dose. When it was dosed in dogs at 4 mg/kg/day for two weeks, M1 levels at 24 h increased from 1.3 μM after the first dose to 13.7 μM after the last dose.
13. K. Takeuchi, A. Tanaka, S. Kato, E. Aihara, and K. Amagase J. Pharmacol. Exp. Ther. 322 2007 903
14. A. Murase, T. Okumura, A. Sakakibara, H. Tonai-Kachi, K. Nakao, and J. Takada Eur. J. Pharmacol. 580 2008 116
15. A. Murase, Y. Taniguchi, H. Tonai-Kachi, K. Nakao, and J. Takada Life Sci. 82 2008 226
16. P. Bertus, and J. Szymoniak J. Org. Chem. 68 2003 7133
17. M.-C. Mathieu, S. Lord-Dufour, V. Bernier, Y. Boie, J.D. Burch, P. Clark, D. Denis, Y. Han, J.R. Mortimer, and A.G. Therien Eur. J. Immunol. 38 2008 1900
18. R.N. Young, X. Billot, Y. Han, D.A. Slipetz, N. Chauret, M. Belley, K. Metters, M.C. Mathieu, G.M. Greig, D. Denis, and M. Girard Heterocycles 64 2004 437
19. C.-C. Chan, S. Boyce, C. Brideau, S. Charleson, W. Cromlish, D. Ethier, J. Evans, A.W. Ford-Hutchinson, M.J. Forrest, J.Y. Gauthier, R. Gordon, M. Gresser, J. Guay, S. Kargman, B. Kennedy, Y. Leblanc, S. Léger, J. Mancini, G.P. O'Neill, M. Ouellet, D. Patrick, M.D. Percival, H. Perrier, P. Prasit, I. Rodger, P. Tagari, M. Therien, P. Vickers, D. Visco, Z. Wang, J. Webb, E. Wong, L.-J. Xu, R.N. Young, R. Zamboni, and D. Riendeau J. Pharmacol. Exp. Ther. 290 1999 551
20. S.E. Rowland, P. Clark, R. Gordon, A.K. Mullen, J. Guay, C. Dufresne, C. Brideau, B. Côté, Y. Ducharme, J. Mancini, C.-C. Chan, L. Audoly, and D. Xu Eur. J. Pharmacol. 560 2007 216